Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Depreciation & Amortization (CF) (2016 - 2024)

Alaunos Therapeutics (TCRT) has disclosed Depreciation & Amortization (CF) for 14 consecutive years, with -$1000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Depreciation & Amortization (CF) fell 100.41% year-over-year to -$1000.0, compared with a TTM value of -$1000.0 through Sep 2025, down 100.41%, and an annual FY2024 reading of $2000.0, down 99.91% over the prior year.
  • Depreciation & Amortization (CF) was -$1000.0 for Q4 2024 at Alaunos Therapeutics, down from $1000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $708000.0 in Q4 2021 and bottomed at -$1000.0 in Q4 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $463368.4, with a median of $673000.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 280.28% in 2021, then crashed 100.41% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $420000.0 in 2020, then surged by 68.57% to $708000.0 in 2021, then decreased by 1.98% to $694000.0 in 2022, then plummeted by 65.27% to $241000.0 in 2023, then plummeted by 100.41% to -$1000.0 in 2024.
  • Business Quant data shows Depreciation & Amortization (CF) for TCRT at -$1000.0 in Q4 2024, $1000.0 in Q2 2024, and $2000.0 in Q1 2024.